The present invention relates to applicators used to apply microneedle arrays to a mammal. The present method also relates to methods of applying a microneedle array or patch to a mammal
Only a limited number of molecules with demonstrated therapeutic value can be transported through the skin, even with the use of approved chemical enhancers. The main barrier to transport of molecules through the skin is the stratum corneum (the outermost layer of the skin).
Devices including arrays of relatively small structures, sometimes referred to as microneedles or micro-pins, have been disclosed for use in connection with the delivery of therapeutic agents and other substances through the skin and other surfaces. The devices are typically pressed against the skin in an effort to pierce the stratum corneum such that the therapeutic agents and other substances can pass through that layer and into the tissues below.
Issues related to applying microneedles include the ability to effectively insert the needles to a desired depth in the skin and the ability to protect the delicate microneedles prior to application to the skin.
The present invention provides an application device for applying a microneedle device to a skin surface comprising a flexible sheet having a raised central area wherein motion of the raised central area in a direction perpendicular to the plane of the flexible sheet drives the microneedle device against the skin. This can provide an applicator that is easy to handle, simple to use, low cost, and suitable for inclusion in a disposable device. It can also have a low-profile design.
In another embodiment, the present invention provides an application device for applying a microneedle device to a skin surface comprising: a flexible sheet having a raised central area attached to the microneedle device and a supporting member at or near the periphery of the flexible sheet, wherein the flexible sheet is configured such that it will undergo a stepwise motion in the direction orthogonal to the major plane of the sheet.
In another embodiment, the present invention provides an application device for applying a microneedle device to a skin surface comprising: a flexible sheet having a raised central area configured so as to be releasably attached to a microneedle device and supporting means at or near the periphery of the flexible sheet, wherein the flexible sheet is configured such that it will undergo a stepwise motion in the direction orthogonal to the major plane of the sheet.
In another embodiment, the present invention provides an application device for applying a microneedle device to a skin surface comprising a flexible sheet having a raised central area wherein motion of the raised central area in a direction perpendicular to the plane of the flexible sheet drives the microneedle device against the skin.
In another embodiment, the present invention provides a method of using any one of the foregoing application devices for applying a microneedle array to a skin surface wherein the application device is placed against a skin surface and a force is applied to the device sufficient to cause the flexible sheet of the device to change from a convex to a concave orientation with respect to the skin surface, thereby driving the microneedle array against the skin.
As used herein, certain terms will be understood to have the meaning set forth below:
“Array” refers to the medical devices described herein that include one or more structures capable of piercing the stratum corneum to facilitate the transdermal delivery of therapeutic agents or the sampling of fluids through or to the skin.
“Microstructure,” “microneedle” or “microarray” refers to the specific microscopic structures associated with the array that are capable of piercing the stratum corneum to facilitate the transdermal delivery of therapeutic agents or the sampling of fluids through the skin. By way of example, microstructures can include needle or needle-like structures as well as other structures capable of piercing the stratum corneum.
The features and advantages of the present invention will be understood upon consideration of the detailed description of the preferred embodiment as well as the appended claims. These and other features and advantages of the invention may be described below in connection with various illustrative embodiments of the invention. The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The Figures and the detailed description which follow more particularly exemplify illustrative embodiments.
Preferred embodiments of the invention will now be described in greater detail below with reference to the attached drawings, wherein:
While the above-identified drawing figures set forth several embodiments of the invention, other embodiments are also contemplated, as noted in the discussion. In all cases, this disclosure presents the invention by way of representation and not limitation. It should be understood that numerous other modifications and embodiments can be devised by those skilled in the art, which fall within the scope and spirit of the principles of the invention. The figures may not be drawn to scale. Like reference numbers may have been used throughout the figures to denote like parts.
One embodiment of the microneedle application device is shown in
The microneedle device 120 may be attached to the flexible sheet 110 by any suitable attachment means. As shown in
As shown in
The microneedle device 120 shown in
Another embodiment of an application device 100 of the present invention is shown in
Another embodiment of an application device 100 of the present invention is shown in
Another embodiment of an application device 200 of the present invention is shown in
Flexible sheets of the present invention may be made from any suitable material, including metals, such as aluminum, steel, such as stainless steel, or tin, and plastics, such as polystyrene, polycarbonate, and polypropylene. The flexible sheet with raised central area may be a single, integral piece. Alternatively, the raised central area may be connected to an outer ring, and may be made from the same or from a different material.
A method of applying a microneedle device using an application device of the present invention involves having the microneedle device reach a desired velocity that is effective to pierce the microneedles into the skin. The desired velocity is controlled to limit or prevent stimulation of the underlying nerve tissue. In connection with the present invention, the maximum velocity achieved by the microneedle device upon impact with the skin is often 20 meters per second (m/s) or less, potentially 15 m/s or less, and possibly 10 m/s or less. In some instances, the maximum velocity may be 8 m/s or less. At the lower end of the range of velocities, the minimum velocity achieved by the microneedle device upon impact with the skin is often 2 m/s or more, potentially 4 m/s or more, and possibly 6 m/s or more.
Because of the variability in the location of skin, the application device may be designed such that the microneedle device travels at a velocity at or above the desired minimum velocities over a distance that is sufficient to accommodate the variations in skin location relative to the application device. For example, the microneedle device in the application device may move at or above the minimum desired velocity over a distance of one millimeter or more.
The force required to reach the desired velocities may vary based on the mass and shape of the microneedle application device, and in particular the mass and shape of the flexible sheet and the microneedle device. The mass of the microneedle application device may be controlled or selected to reduce the likelihood that nerve tissue underneath the delivery site is stimulated sufficiently to result in the sensation of pain. For example, it may be preferred that the mass of the microneedle application device be about 6 grams or less, more preferably about 4 grams or less.
In one embodiment, the microneedle device shown schematically as 120 in
In an alternative embodiment (not shown) the applicator itself includes adhesive on its perimeter, skin-contacting surface, so that the entire applicator can be adhered in place after actuation with the microneedles into the skin for a desired period.
The microneedle devices useful in the various embodiments of the invention may comprise any of a variety of configurations, such as those described in the following patents and patent applications, the disclosures of which are herein incorporated by reference. One embodiment for the microneedle devices comprises the structures disclosed in United States Patent Application Publication No. 2003/0045837. The disclosed microstructures in the aforementioned patent application are in the form of microneedles having tapered structures that include at least one channel formed in the outside surface of each microneedle. The microneedles may have bases that are elongated in one direction. The channels in microneedles with elongated bases may extend from one of the ends of the elongated bases towards the tips of the microneedles. The channels formed along the sides of the microneedles may optionally be terminated short of the tips of the microneedles. The microneedle arrays may also include conduit structures formed on the surface of the substrate on which the microneedle array is located. The channels in the microneedles may be in fluid communication with the conduit structures. Another embodiment for the microneedle devices comprises the structures disclosed in co-pending U.S. patent application Ser. No. 10/621,620 filed on Jul. 17, 2003 which describes microneedles having a truncated tapered shape and a controlled aspect ratio. Still another embodiment for the microneedle devices comprises the structures disclosed in U.S. Pat. No. 6,091,975 (Daddona, et al.) which describes blade-like microprotrusions for piercing the skin. Still another embodiment for the microneedle devices comprises the structures disclosed in U.S. Pat. No. 6,313,612 (Sherman, et al.) which describes tapered structures having a hollow central channel. Still another embodiment for the micro arrays comprises the structures disclosed in International Publication No. WO 00/74766 (Garstein, et al.) which describes hollow microneedles having at least one longitudinal blade at the top surface of tip of the microneedle.
Microneedle devices suitable for use in the present invention may be used to deliver drugs (including any pharmacological agent or agents) through the skin in a variation on transdermal delivery, or to the skin for intradermal or topical treatment, such as vaccination.
In one aspect, drugs that are of a large molecular weight may be delivered transdermally. Increasing molecular weight of a drug typically causes a decrease in unassisted transdermal delivery. Microneedle devices suitable for use in the present invention have utility for the delivery of large molecules that are ordinarily difficult to deliver by passive transdermal delivery. Examples of such large molecules include proteins, peptides, nucleotide sequences, monoclonal antibodies, DNA vaccines, polysaccharides, such as heparin, and antibiotics, such as ceftriaxone.
In another aspect, microneedle devices suitable for use in the present invention may have utility for enhancing or allowing transdermal delivery of small molecules that are otherwise difficult or impossible to deliver by passive transdermal delivery. Examples of such molecules include salt forms; ionic molecules, such as bisphosphonates, preferably sodium alendronate or pamedronate; and molecules with physicochemical properties that are not conducive to passive transdermal delivery.
In another aspect, microneedle devices suitable for use in the present invention may have utility for enhancing delivery of molecules to the skin, such as in dermatological treatments, vaccine delivery, or in enhancing immune response of vaccine adjuvants. In one aspect, the drug may be applied to the skin (e.g., in the form of a solution that is swabbed on the skin surface or as a cream that is rubbed into the skin surface) prior to applying the microneedle device.
Microneedle devices may be used for immediate delivery, that is where they are applied and immediately removed from the application site, or they may be left in place for an extended time, which may range from a few minutes to as long as 1 week. In one aspect, an extended time of delivery may from 1 to 30 minutes to allow for more complete delivery of a drug than can be obtained upon application and immediate removal. In another aspect, an extended time of delivery may be from 4 hours to 1 week to provide for a sustained release of drug.
A device as generally shown in
The device of example 1 was tested according to the general mode of operation shown in
The present invention has been described with reference to several embodiments thereof. The foregoing detailed description and examples have been provided for clarity of understanding only, and no unnecessary limitations are to be understood therefrom. It will be apparent to those skilled in the art that many changes can be made to the described embodiments without departing from the spirit and scope of the invention. Thus, the scope of the invention should not be limited to the exact details of the compositions and structures described herein, but rather by the language of the claims that follow.
This application is a continuation of U.S. patent application Ser. No. 11/718,465, filed May 2, 2007, now U.S. Pat. No. 8,267,889, which is a national stage filing under 35 U.S.C. 371 of PCT/US2005/041854 filed Nov. 18, 2005, which claims priority to U.S. Provisional Application Ser. No. 60/629,215, filed on Nov. 18, 2004, the disclosure of which is incorporated herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3034507 | McConnell et al. | May 1962 | A |
3072122 | Rosenthal | Jan 1963 | A |
3123212 | Taylor et al. | Mar 1964 | A |
3136314 | Kravitz | Jun 1964 | A |
RE25637 | Kravitz et al. | Sep 1964 | E |
3221740 | Rosenthal | Dec 1965 | A |
3246647 | Taylor et al. | Apr 1966 | A |
3322121 | Banker | May 1967 | A |
3466131 | Arcudi | Sep 1969 | A |
3510933 | Taylor et al. | May 1970 | A |
3512520 | Cowan | May 1970 | A |
3596660 | Melone | Aug 1971 | A |
3675766 | Rosenthal | Jul 1972 | A |
3678150 | Szumski et al. | Jul 1972 | A |
3688764 | Reed et al. | Sep 1972 | A |
3905371 | Stickl et al. | Sep 1975 | A |
3964482 | Gerstel et al. | Jun 1976 | A |
4109655 | Chacornac | Aug 1978 | A |
4237906 | Havstad et al. | Dec 1980 | A |
4304241 | Brennan | Dec 1981 | A |
4360016 | Sarrine | Nov 1982 | A |
4453926 | Galy | Jun 1984 | A |
4474751 | Haslam et al. | Oct 1984 | A |
4503856 | Cornell et al. | Mar 1985 | A |
4517978 | Levin et al. | May 1985 | A |
4637403 | Garcia et al. | Jan 1987 | A |
4858607 | Jordan et al. | Aug 1989 | A |
4869249 | Crossman et al. | Sep 1989 | A |
4920977 | Haynes | May 1990 | A |
4924879 | O'Brien | May 1990 | A |
5192535 | Davis et al. | Mar 1993 | A |
5250023 | Lee et al. | Oct 1993 | A |
5318584 | Lange et al. | Jun 1994 | A |
5340572 | Patel et al. | Aug 1994 | A |
5366469 | Steg et al. | Nov 1994 | A |
5368047 | Suzuki et al. | Nov 1994 | A |
5402798 | Swierczek et al. | Apr 1995 | A |
5487726 | Rabenau et al. | Jan 1996 | A |
5611806 | Jang | Mar 1997 | A |
5879326 | Godshall et al. | Mar 1999 | A |
5983136 | Kamen | Nov 1999 | A |
6050988 | Zuck | Apr 2000 | A |
6091975 | Daddona et al. | Jul 2000 | A |
6132755 | Eicher et al. | Oct 2000 | A |
6219574 | Cormier et al. | Apr 2001 | B1 |
6256533 | Yuzhakov et al. | Jul 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6312612 | Sherman et al. | Nov 2001 | B1 |
6322808 | Trautman et al. | Nov 2001 | B1 |
6334856 | Allen et al. | Jan 2002 | B1 |
6379324 | Gartstein et al. | Apr 2002 | B1 |
6440096 | Lastovich et al. | Aug 2002 | B1 |
6454755 | Godshall | Sep 2002 | B1 |
6503231 | Prausnitz et al. | Jan 2003 | B1 |
6532386 | Sun et al. | Mar 2003 | B2 |
6537242 | Palmer | Mar 2003 | B1 |
6589202 | Powell | Jul 2003 | B1 |
6591124 | Sherman et al. | Jul 2003 | B2 |
6595947 | Mikszta et al. | Jul 2003 | B1 |
6603998 | King et al. | Aug 2003 | B1 |
6611707 | Prausnitz et al. | Aug 2003 | B1 |
6623457 | Rosenberg | Sep 2003 | B1 |
6713291 | King et al. | Mar 2004 | B2 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6780171 | Gabel et al. | Aug 2004 | B2 |
6797276 | Glenn et al. | Sep 2004 | B1 |
6830562 | Mogensen et al. | Dec 2004 | B2 |
6855131 | Trautman et al. | Feb 2005 | B2 |
6881203 | Delmore et al. | Apr 2005 | B2 |
6881538 | Haddad et al. | Apr 2005 | B1 |
6890319 | Crocker | May 2005 | B1 |
6908453 | Fleming et al. | Jun 2005 | B2 |
6931277 | Yuzhakov et al. | Aug 2005 | B1 |
7004928 | Aceti et al. | Feb 2006 | B2 |
7250037 | Shermer et al. | Jul 2007 | B2 |
7419481 | Trautman et al. | Sep 2008 | B2 |
7455654 | Cormier et al. | Nov 2008 | B2 |
7798987 | Trautman et al. | Sep 2010 | B2 |
20010044606 | Inkpen et al. | Nov 2001 | A1 |
20020032415 | Trautman et al. | Mar 2002 | A1 |
20020082543 | Park et al. | Jun 2002 | A1 |
20020087182 | Trautman et al. | Jul 2002 | A1 |
20020091357 | Trautman et al. | Jul 2002 | A1 |
20020095134 | Pettis et al. | Jul 2002 | A1 |
20020111600 | Cormier et al. | Aug 2002 | A1 |
20020123675 | Trautman et al. | Sep 2002 | A1 |
20020128599 | Cormier et al. | Sep 2002 | A1 |
20020138049 | Allen et al. | Sep 2002 | A1 |
20020169416 | Gonnelli et al. | Nov 2002 | A1 |
20020177839 | Cormier et al. | Nov 2002 | A1 |
20020177858 | Sherman et al. | Nov 2002 | A1 |
20020188245 | Martin et al. | Dec 2002 | A1 |
20020193729 | Cormier et al. | Dec 2002 | A1 |
20020198509 | Mikszta et al. | Dec 2002 | A1 |
20030045837 | Delmore et al. | Mar 2003 | A1 |
20030050602 | Pettis et al. | Mar 2003 | A1 |
20030083641 | Angel et al. | May 2003 | A1 |
20030083645 | Angel et al. | May 2003 | A1 |
20030135158 | Gonnelli | Jul 2003 | A1 |
20030135161 | Fleming et al. | Jul 2003 | A1 |
20030161869 | Hatanaka et al. | Aug 2003 | A1 |
20030181863 | Ackley et al. | Sep 2003 | A1 |
20030199811 | Sage, Jr. et al. | Oct 2003 | A1 |
20030199812 | Rosenberg | Oct 2003 | A1 |
20030208167 | Prausnitz et al. | Nov 2003 | A1 |
20040049150 | Dalton et al. | Mar 2004 | A1 |
20040077994 | Lastovich et al. | Apr 2004 | A1 |
20040138612 | Shermer et al. | Jul 2004 | A1 |
20040176732 | Frazier et al. | Sep 2004 | A1 |
20040181203 | Cormier et al. | Sep 2004 | A1 |
20050025778 | Cormier et al. | Feb 2005 | A1 |
20050027242 | Gabel et al. | Feb 2005 | A1 |
20050065463 | Tobinaga et al. | Mar 2005 | A1 |
20050065466 | Vedrine | Mar 2005 | A1 |
20050065472 | Cindrich et al. | Mar 2005 | A1 |
20050096586 | Trautman et al. | May 2005 | A1 |
20050106226 | Cormier et al. | May 2005 | A1 |
20050137525 | Wang et al. | Jun 2005 | A1 |
20050228313 | Kaler et al. | Oct 2005 | A1 |
20050261631 | Clarke et al. | Nov 2005 | A1 |
20070021716 | Hansen | Jan 2007 | A1 |
20070073220 | Bunce | Mar 2007 | A1 |
20070161964 | Yuzhakov | Jul 2007 | A1 |
20080051699 | Choi et al. | Feb 2008 | A1 |
20080088066 | Ferguson et al. | Apr 2008 | A1 |
20080114298 | Cantor et al. | May 2008 | A1 |
20080195035 | Frederickson et al. | Aug 2008 | A1 |
20090198189 | Simons et al. | Aug 2009 | A1 |
20100222743 | Frederickson et al. | Sep 2010 | A1 |
20120109066 | Chase et al. | May 2012 | A1 |
Number | Date | Country |
---|---|---|
2005200910 82 | Mar 2005 | AU |
407063 | Jan 1991 | EP |
1080986 | Aug 1967 | GB |
2064329 | Jun 1981 | GB |
2221394 | Feb 1990 | GB |
6-22941 | Feb 1994 | JP |
2002-504904 | Feb 2002 | JP |
2003-321350 | Nov 2003 | JP |
2003-534881 | Nov 2003 | JP |
WO 9610630 | Apr 1996 | WO |
WO 9855109 | Dec 1998 | WO |
WO 0074766 | Dec 2000 | WO |
WO 0136037 | May 2001 | WO |
WO 0193931 | Dec 2001 | WO |
WO 04000389 | Dec 2003 | WO |
WO 2004009172 | Jan 2004 | WO |
WO 2005051455 | Jun 2005 | WO |
WO 2005051476 | Jun 2005 | WO |
WO 2005058393 | Jun 2005 | WO |
WO 2005065765 | Jul 2005 | WO |
WO 2005082596 | Sep 2005 | WO |
WO 2005123173 | Dec 2005 | WO |
WO 2006055795 | May 2006 | WO |
WO 2006055802 | May 2006 | WO |
WO 2007002521 | Jan 2007 | WO |
WO 2007002523 | Jan 2007 | WO |
WO 2011014514 | Feb 2011 | WO |
Entry |
---|
ASTM 0256—06a Standard Test Methods for Determining the Izod Pendulum Impact Resistance of Plastics; 20 pgs. |
ASTM D638—08 Standard Test Method for Tensile Properties of Plastics; 16 pgs. |
ASTM D 1238—04c Standard Test Method for Melt Flow Rates of Thermoplastics by Extrusion Plastometer; 14 pgs. |
U.S. Appl. No. 60/578,651, filed Jun. 10, 2004, Frederickson et al. |
Daddona Current Opinion in Drug Discovery and Development 1999 2(2);168-171. |
Kaushik et al. Anesthesia Analg., 2001, 92, 502-504. |
Henry et al. J. Pharm.Sci., 1998, 87,8,922-925. |
McAllister et al. (1) Annual Review of Biomedical Engineering, 2000, 2, 289-313. |
McAllister et al. (2) Proceed. Int'l. Symp. Control Release of Bioactive Material, 26, (1999), CRS, 192-193. |
Number | Date | Country | |
---|---|---|---|
20130006219 A1 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
60629215 | Nov 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11718465 | US | |
Child | 13611942 | US |